Sight Sciences, Inc.
SGHT
NASDAQ·Healthcare·Medical - Devices·Mkt cap $454.3M
$8.35
▼ -0.36%
P/E
-14.95
Mkt Cap
$454.3M
52-Wk Range
$3.19–$9.24
52-Week Range
$3.19 - $9.24
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 126.3% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary minimally invasive surgical technology reducing procedural complexity and recovery time
- Wearable device innovation addressing dry eye disease with non-pharmacological approach
- Established distribution network across U.S. hospitals, medical centers, and eyecare professionals
- Dual-indication portfolio addressing two high-prevalence eye conditions with significant unmet needs
Bear Case
1 risk
- High volatility (beta 2.5). Larger-than-normal price swings expected.
Growth
Stable outlook
Rising glaucoma prevalence driven by aging demographics and increased disease awareness
Value
Deep value opportunity - significant discount to Medical Devices peers
Momentum
Hot
+80.3% over 3m
Quality
Excellent
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SGHT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 5, 2026
Reported EPS of -$0.08 vs -$0.18 consensus (+56.4% surprise). Revenue of $23.4M vs $21.7M expected (+7.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+56.4%
Revenue trend · last 8Q
—
+2%
-9%
-8%
-1%
+7%
+13%
+20%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$20.2M
$19.1M
$17.5M
$19.6M
$19.9M
$20.4M
$19.7M
$23.4M
Margins · last 8Q
Gross
91.4%
Operating
-16.6%
Profit
-19.0%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 13, 2026
vs Industry
How SGHT stacks vs Medical - Devices
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related